hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-21. Anything still debated is marked as such rather than presented as settled.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
== Formation == Initial funding for the formation of Onyx came from biotechnology firm Chiron Corporation (granted a 43% stake in the new company) and venture capital investors: Avalon Ventures, Institutional Venture Partners (IVP), J. H. Whitney & Company and Kleiner Perkins. McCormick had been working on cancer treatments at Chiron before he was selected as vice president of research at the newly formed company, leading the company's research program. The acting president of the firm at its inception was Samuel D. Colella, a partner at early investor, IVP.
== Intermediates for other pathways == This article concentrates on the catabolic role of glycolysis with regard to converting potential chemical energy to usable chemical energy during the oxidation of glucose to pyruvate. Many of the metabolites in the glycolytic pathway are also used by anabolic pathways, and, as a consequence, flux through the pathway is critical to maintain a supply of carbon skeletons for biosynthesis. The following metabolic pathways are all strongly reliant on glycolysis as a source of metabolites: and many more.
== Further reading == Brady JE, Humiston GE & Heikkinen H (1980), "Chemistry of the Representative Elements: Part II, The Metalloids and Nonmetals", in General Chemistry: Principles and Structure, 2nd ed., SI version, John Wiley & Sons, New York, pp. 537–91, ISBN 0-471-06315-0 Chedd G (1969), Half-way Elements: The Technology of Metalloids, Doubleday, New York Choppin GR & Johnsen RH (1972), "Group IV and the Metalloids", in Introductory Chemistry, Addison-Wesley, Reading, Massachusetts, pp. 341–57 Dunstan S (1968), "The Metalloids", in Principles of Chemistry, D. Van Nostrand Company, London, pp. 407–39 Goldsmith RH (1982), "Metalloids", Journal of Chemical Education, vol. 59, no. 6, pp. 526527, doi:10.1021/ed059p526 Hawkes SJ (2001), "Semimetallicity", Journal of Chemical Education, vol. 78, no. 12, pp. 1686–87, doi:10.1021/ed078p1686 Metcalfe HC, Williams JE & Castka JF (1974), "Aluminum and the Metalloids", in Modern Chemistry, Holt, Rinehart and Winston, New York, pp. 538–57, ISBN 0-03-089450-6 Miller JS (2019), "Viewpoint: Metalloids – An Electronic Band Structure Perspective", Chemistry – A European Perspective, preprint version, doi:10.1002/chem.201903167 Moeller T, Bailar JC, Kleinberg J, Guss CO, Castellion ME & Metz C (1989), "Carbon and the Semiconducting Elements", in Chemistry, with Inorganic Qualitative Analysis, 3rd ed., Harcourt Brace Jovanovich, San Diego, pp. 742–75, ISBN 0-15-506492-4 Parveen N et al.
Sources: en.wikipedia.org
=== Cardiovascular health === The Food and Drug Administration (FDA) granted the following health claim for soy: "25 grams of soy protein a day, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease." One serving of 1 cup (~240 mL) of soy milk, for instance, contains 6 or 7 grams of soy protein. An American Heart Association (AHA) review of a decade long study of soy protein benefits did not recommend isoflavone supplementation. The review panel also found that soy isoflavones have not been shown to reduce post-menopausal "hot flashes" and the efficacy and safety of isoflavones to help prevent cancers of the breast, uterus or prostate is in question. AHA concluded that "many soy products should be beneficial to cardiovascular and overall health because of their high content of polyunsaturated fats, fiber, vitamins, and minerals and low content of saturated fat". Other studies found that soy protein consumption could lower the concentration of low-density lipoproteins (LDL) transporting fats in the extracellular water to cells.
centrifugation A laboratory technique which involves the application of centrifugal force to separate particles from a solution according to their size, shape, and density. Larger and/or denser substances migrate away from the axis of a centrifuge, while smaller and/or less dense substances migrate towards the axis.
== Multi-substrate reactions == Multi-substrate reactions follow complex rate equations that describe how the substrates bind and in what sequence. The analysis of these reactions is much simpler if the concentration of substrate A is kept constant and substrate B varied. Under these conditions, the enzyme behaves just like a single-substrate enzyme, and a plot of v by [S] gives apparent KM and Vmax constants for substrate B. If a set of these measurements is performed at different fixed concentrations of A, these data can be used to work out what the mechanism of the reaction is. For an enzyme that takes two substrates A and B and turns them into two products P and Q, there are two types of mechanism: ternary complex and substituted-enzyme mechanisms. Ternary-complex mechanisms
Sources: en.wikipedia.org
In the United States, the term "nickel" or "nick" originally applied to the copper-nickel Flying Eagle cent, which replaced copper with 12% nickel 1857–58, then the Indian Head cent of the same alloy from 1859 to 1864. Still later, in 1865, the term designated the three-cent nickel, with nickel increased to 25%. In 1866, the five-cent shield nickel (25% nickel, 75% copper) appropriated the designation, which has been used ever since for the subsequent 5-cent pieces. This alloy proportion is not ferromagnetic. The US nickel coin contains 0.04 ounces (1.1 g) of nickel, which at the April 2007 price was worth 6.5 cents, along with 3.75 grams of copper worth about 3 cents, with a total metal value of more than 9 cents. Since the face value of a nickel is 5 cents, this made it an attractive target for melting by people wanting to sell the metals at a profit. The United States Mint, anticipating this practice, implemented new interim rules on December 14, 2006, subject to public comment for 30 days, which criminalized the melting and export of cents and nickels. Violators can be punished with a fine of up to $10,000 and/or a maximum of five years in prison. As of February 19, 2025, the melt value of a US nickel (copper and nickel included) is $0.054 (108% of the face value).
By the time of nominations closing in April 2026, however, Galloway was no longer standing as a constituency candidate in Glasgow Southside, though remained on the regional ballot. He was unsuccessful, as were all other Workers Party candidates in the election. On 27 September 2025, while returning from Moscow through Abu Dhabi, George Galloway and his wife Putri Gayatri Pertiwi were stopped and questioned at Gatwick Airport by the Metropolitan Police's Counter Terrorism Command under the Counter-Terrorism and Border Security Act 2019 and questioned on his opinions of Russia, and China. His party condemned this as "politically motivated intimidation". The Metropolitan Police said "Neither of them were arrested and they were allowed on their way". Following the arrest Galloway entered a "self-imposed exile" in Russia. On the 4 September 2026, the Bank of Scotland closed Galloway's account prompting him to condemn the bank on X, saying "I will not stand by while you use your usurious power to wreck my family life." on the matter. In preparation for the 2026 Greater Manchester mayoral by-election, Galloway announced his candidacy on 19 June 2026. However, when nominations were released on 6 July, he was not listed as a candidate and was not included on the ballot. On the 14 September 2026 George Galloway announced his intention to stand in the 2026 Holborn and St. Pancras by-election on his podcast, MOATS.
== Figurative uses == The use of the word "juice" to mean "liquor" (alcohol) dates from 1828. The use of the term "juice" to mean "electricity" dates from 1896. As a verb, the word "juice" was first recorded as meaning "to enliven" in 1964. The adjective "juiced" is recorded as meaning "drunk" in 1946 and "enhanced or as if enhanced by steroids" in 2003. The adjective "juicy" has meant "succulent" since the 15th century (e.g., a juicy roast beef). The figurative meaning "wealthy, full of some desired quality" dates from the 1620s (e.g., a pirate calling a heavily laden ship he aims to plunder a "juicy catch"). The meaning "lively, suggestive, racy, sensational" (e.g., a juicy scandal) is from 1883.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.